SPAC30C2.07 Antibody

What is the SPAC30C2.07 protein and what are its known functions in S. pombe?

SPAC30C2.07 is a protein encoded by the corresponding gene in Schizosaccharomyces pombe. While comprehensive characterization is still ongoing, research indicates it may be involved in chromatin-associated processes based on proteomic analyses of chromatin-bound proteins in fission yeast . The protein has been assigned UniProt number Q9P6K4 , and studies suggest it could play roles in cellular pathways that are evolutionarily conserved across eukaryotes.

What are the recommended storage conditions for SPAC30C2.07 antibody?

For optimal preservation of antibody activity, store SPAC30C2.07 antibody at -20°C or -80°C upon receipt. It's crucial to avoid repeated freeze-thaw cycles, as these can compromise antibody integrity and function. The antibody is supplied in a storage buffer containing preservative (0.03% Proclin 300) and constituents (50% Glycerol, 0.01M PBS, pH 7.4) that help maintain its stability . For long-term storage, aliquoting the antibody before freezing is recommended to minimize freeze-thaw cycles.

What are the validated applications for SPAC30C2.07 antibody?

The SPAC30C2.07 antibody has been validated for ELISA and Western blot (WB) applications to ensure proper identification of the antigen . These applications allow researchers to detect the presence and relative abundance of the target protein in various experimental setups. The antibody has been specifically tested for reactivity with Schizosaccharomyces pombe (strain 972 / ATCC 24843) , making it suitable for yeast-focused research studies.

How does SPAC30C2.07 antibody perform in chromatin immunoprecipitation (ChIP) experiments?

While the SPAC30C2.07 antibody has not been explicitly validated for ChIP applications in the provided data, researchers working with chromatin-bound proteins often adapt antibodies validated for Western blotting to ChIP protocols. Based on studies examining chromatin-bound proteins in S. pombe , a potential experimental approach would include:

• Crosslinking yeast cells with formaldehyde

• Lysing cells and sonicating to shear chromatin

• Immunoprecipitating with SPAC30C2.07 antibody

• Reversal of crosslinks and DNA purification

• Analysis of associated DNA by qPCR or sequencing

Optimization is essential as polyclonal antibodies can vary in their ChIP efficiency. Controls should include a non-specific IgG antibody and input chromatin samples.

What considerations should be taken when using SPAC30C2.07 antibody in studies of retrotransposon integration?

Recent research has identified host factors in S. pombe that promote retrotransposon integration . When investigating whether SPAC30C2.07 plays a role in this process, several considerations apply:

• Experimental design: Implement a genome-wide screen combining transposition assay with genetic assay measuring cDNA recombination to identify factors contributing to integration.

• Controls: Include appropriate deletion strains as controls (based on the 3,004 S. pombe strains with single gene deletions mentioned in the research) .

• Validation: Verify findings through immunoblot measures of Tf1 proteins and integration assays.

• Data interpretation: Consider that the consensus from existing studies provides an opportunity to design experiments that test specific pathways for mechanisms driving integration of retrotransposons .

The antibody can be used to monitor SPAC30C2.07 protein levels in different genetic backgrounds to correlate with integration efficiency.

How can SPAC30C2.07 antibody be validated for specificity in complex protein mixtures?

Validating antibody specificity is crucial for reliable research outcomes. A comprehensive validation protocol should include:

• Western blot analysis with:

  • Wild-type S. pombe lysate (positive control)

  • SPAC30C2.07 deletion strain lysate (negative control)

  • Recombinant SPAC30C2.07 protein (specificity control)

• Immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody.

• Cross-reactivity testing against closely related proteins in the S. pombe proteome.

• Peptide competition assay: Pre-incubating the antibody with excess immunizing peptide should abolish specific signals.

This approach aligns with recent findings highlighting that many commercial antibodies fail specificity tests, with only ~48% of antibodies recognizing their intended targets in Western blotting . Recombinant antibodies generally perform better than polyclonal antibodies, but proper validation remains essential regardless of antibody type.

What are the optimal dilutions and conditions for Western blot applications using SPAC30C2.07 antibody?

For optimal Western blot results with SPAC30C2.07 antibody, follow this methodology:

• Sample preparation:

  • Prepare S. pombe lysates under denaturing conditions (SDS-PAGE)

  • Load 20-50 μg of total protein per lane

  • Include positive and negative controls

• Antibody dilution:

  • Starting dilution range: 1:500 to 1:1000

  • Optimize based on signal-to-noise ratio

  • Dilute in blocking buffer containing 0.1% Tween-20

• Incubation conditions:

  • Primary antibody: Overnight at 4°C or 2 hours at room temperature

  • Secondary antibody: Anti-rabbit HRP conjugate at 1:5000 for 1 hour at room temperature

• Detection:

  • Enhanced chemiluminescence (ECL) substrate

  • Exposure time: Start with 30 seconds and adjust as needed

Always perform titration experiments to determine the optimal antibody concentration for your specific experimental conditions, as protein expression levels may vary between strains and growth conditions.

What controls should be included when using SPAC30C2.07 antibody in immunofluorescence experiments?

Though not explicitly validated for immunofluorescence in the provided data, if adapting this antibody for such applications, the following controls are essential:

• Positive control: Wild-type S. pombe expressing SPAC30C2.07

• Negative controls:

  • SPAC30C2.07 deletion strain

  • Primary antibody omission

  • Pre-immune serum at equivalent concentration (available as a component )

  • Secondary antibody only

• Specificity controls:

  • Peptide competition assay

  • Alternative antibody targeting same protein (if available)

• Subcellular marker controls:

  • Nuclear marker (e.g., DAPI)

  • Other relevant organelle markers depending on expected localization

These controls help distinguish true signals from background fluorescence and non-specific binding, particularly important when establishing subcellular localization of previously uncharacterized proteins.

How should quantitative proteomic analysis be designed when studying SPAC30C2.07 in chromatin-bound fractions?

Based on the research of chromatin-bound proteins in S. pombe , a robust quantitative proteomic analysis should follow this methodology:

• Experimental design:

  • Implement ChIP-on-chip approach to determine DNA binding sites

  • Include wild-type and SPAC30C2.07 deletion strains

  • Perform biological triplicates for statistical validity

• Sample preparation:

  • Isolate chromatin fractions using established protocols

  • Process samples for mass spectrometry analysis

  • Label peptides with isotopic tags for quantification (e.g., SILAC, TMT)

• Data acquisition and analysis:

  • Perform LC-MS/MS using high-resolution mass spectrometry

  • Apply appropriate statistical methods for differential analysis:

    • Calculate mean, SD, variance, skewness, kurtosis

    • Generate box plots for data visualization

    • Apply inferential statistics to measure relationships between variables

• Validation:

  • Confirm key findings with orthogonal methods (Western blot, ChIP-qPCR)

  • Assess protein-protein interactions through co-immunoprecipitation

This approach enables comprehensive characterization of SPAC30C2.07's role in chromatin-associated processes and its interacting partners.

How should discrepancies between antibody-based detection methods be resolved when studying SPAC30C2.07?

When facing discrepancies between different detection methods (e.g., Western blot vs. immunofluorescence), follow this systematic approach:

• Methodological validation:

  • Verify antibody specificity in each application independently

  • Confirm epitope accessibility in different sample preparation methods

  • Evaluate potential post-translational modifications affecting recognition

• Technical troubleshooting:

  • Adjust antibody concentration and incubation conditions

  • Modify sample preparation protocols

  • Test alternative blocking reagents to reduce background

• Data integration framework:

  • Apply exploratory data analysis techniques to understand patterns

  • Use statistics appropriate to the measurement level of variables

  • Consider nonlinear analysis if dealing with complex dynamic effects

• Orthogonal validation:

  • Employ multiple antibodies targeting different epitopes

  • Utilize genetic approaches (tagging, deletion) for confirmation

  • Consider mass spectrometry-based validation

The research literature indicates that antibodies can perform differently across applications, with context-dependent performance being common . Third-party validation of antibodies is highly recommended to ensure reliability .

What statistical approaches are most appropriate for analyzing SPAC30C2.07 expression data across different experimental conditions?

For robust statistical analysis of SPAC30C2.07 expression data:

• Exploratory data analysis:

  • Generate descriptive statistics (mean, median, standard deviation)

  • Create visualization tools (scatter plots, box plots) to identify patterns

  • Assess data distribution (normal vs. non-normal)

• Comparative analysis:

  • For normally distributed data: t-tests or ANOVA

  • For non-normal data: non-parametric tests (Mann-Whitney U, Kruskal-Wallis)

  • For time-series data: repeated measures ANOVA or mixed-effects models

• Correlation analysis:

  • Pearson correlation for linear relationships between variables

  • Spearman rank correlation for non-parametric data

  • Multiple regression for complex relationships

• Advanced statistical considerations:

  • Address missing data through appropriate imputation techniques

  • Handle outliers using robust analysis methods

  • Consider bootstrapping for small sample sizes

• Reporting standards:

  • Include p-values, confidence intervals, and effect sizes

  • Report exact statistical tests used

  • Present both raw data and derived statistical measures

How can researchers distinguish between specific and non-specific signals when using SPAC30C2.07 antibody in complex experimental systems?

Distinguishing specific from non-specific signals requires rigorous methodology:

Recent research has highlighted concerns about antibody specificity, with studies showing that many commercial antibodies fail to recognize their intended targets or bind to additional non-target proteins . A study published in eLife demonstrated that only about one-third of polyclonal antibodies recognize their targets in the applications they're recommended for .

To address these challenges:

• Implement rigorous controls in each experiment

• Consider alternative detection methods for confirmation

• Use CRISPR-Cas9 knockout systems as negative controls when possible

• Document all validation steps thoroughly to ensure reproducibility

By combining these approaches, researchers can confidently distinguish specific SPAC30C2.07 signals from background and non-specific interactions.

How can SPAC30C2.07 antibody be used to investigate protein-protein interactions in S. pombe?

To investigate SPAC30C2.07 protein interactions, implement this methodology:

• Co-immunoprecipitation (Co-IP):

  • Lyse S. pombe cells under non-denaturing conditions

  • Immunoprecipitate with SPAC30C2.07 antibody

  • Analyze precipitated proteins by:

    • Western blot for known/suspected interactors

    • Mass spectrometry for unbiased discovery of binding partners

• Proximity labeling approaches:

  • Create fusion proteins (SPAC30C2.07-BioID or SPAC30C2.07-APEX2)

  • Express in S. pombe and activate labeling

  • Purify biotinylated proteins and identify by mass spectrometry

• Yeast two-hybrid screening:

  • Use SPAC30C2.07 as bait protein

  • Screen against S. pombe cDNA library

  • Validate positive interactions with Co-IP

• Functional validation:

  • Generate deletion strains of identified interactors

  • Assess phenotypic consequences

  • Perform epistasis analysis to establish pathway relationships

These approaches provide complementary data about SPAC30C2.07 interactions, helping to establish its role in cellular processes and potential involvement in retrotransposon integration mechanisms .

What are the best practices for using SPAC30C2.07 antibody in studies of gene expression regulation?

For investigating SPAC30C2.07's role in gene expression regulation:

• Chromatin Immunoprecipitation followed by sequencing (ChIP-seq):

  • Cross-link S. pombe cells to preserve protein-DNA interactions

  • Immunoprecipitate with SPAC30C2.07 antibody

  • Sequence associated DNA fragments

  • Analyze binding patterns relative to genomic features:

    • Promoters

    • Enhancers

    • Transcription start sites

    • Gene bodies

• Gene expression correlation:

  • Manipulate SPAC30C2.07 levels (overexpression, deletion)

  • Perform RNA-seq to identify affected transcripts

  • Correlate binding sites with expression changes

• Functional assays:

  • Reporter gene assays with identified target promoters

  • CRISPR interference at binding sites

  • Protein-protein interaction studies with transcriptional machinery

• Integrative analysis:

  • Combine ChIP-seq, RNA-seq, and protein interaction data

  • Identify direct vs. indirect regulatory effects

  • Construct gene regulatory networks